Article

Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.

Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Molecular Therapy (Impact Factor: 7.04). 10/2004; 10(3):525-32. DOI: 10.1016/j.ymthe.2004.05.027
Source: PubMed

ABSTRACT We have produced prolonged, high local concentrations of interferon in vivo by intravesical instillation of adenoviruses encoding interferon-alpha (Ad-IFNalpha) together with the gene transfer-enhancing agent Syn3. We found sustained interferon protein levels for days, both in normal mouse urothelium and in human bladder cancer cells growing as superficial bladder tumors in nude mice using an orthotopic bladder model developed by us. Tumor burden in the bladder was determined utilizing cancer cells containing the green fluorescent protein. Marked tumor regression was observed following two 1-h exposures of Ad-IFNalpha/Syn3 and little or no cytotoxicity was detected in normal cells. Similar intravesical instillation of clinically relevant concentrations of IFN protein alone or Ad-IFNalpha without Syn3 was ineffective. Surprisingly, in vitro, Ad-IFNalpha also caused caspase-dependent death of bladder cancer cell lines that were resistant to high concentrations of IFN-alpha protein, including the cell line used in vivo. These findings demonstrate that Ad-IFNalpha can overcome resistance to IFN-alpha protein both in vitro and in vivo and support evaluation of intravesical Ad-IFNalpha/Syn3 for the treatment of superficial bladder cancer.

0 Bookmarks
 · 
80 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: KU7 is a popular urothelial carcinoma cell line that was isolated from the bladder of a patient at the Keio University (KU) in 1980. It has subsequently been widely used in laboratories around the world. Here we describe how routine cell line authentication has revealed that KU7 was cross-contaminated almost 30 years ago with HeLa, a cervical carcinoma cell line. MATERIALS AND METHODS: Presumed KU7 clones dating from 1984 to 1999 were provided by MD Anderson Cancer Center (MDACC), the Vancouver Prostate Centre (VPC), Kyoto University, Tokyo Medical University and KU, and HeLa was purchased from the ATCC. Genomic DNA was isolated and short tandem repeat (STR) analysis was performed by the Characterized Cell Line Core Facility at MDACC, the Fragment Analysis Facility at Johns Hopkins University and the RIKEN Bioresource Center (Japan). Comparative genomic hybridization (CGH) was performed on the Agilent platform at the VPC. RESULTS: The STR profile of all KU7 clones was an exact match with HeLa. The CGH of all samples revealed an abundance of shared chromosomal aberrations. Slight differences in some genomic areas are explained by genomic drift occurring in different KU7 clones separated by many years. CONCLUSIONS: Our analysis identified that a cross-contamination of KU7 with HeLa occurred prior to 1984 at the source institution. All KU7 clones in the urologic literature should be considered HeLa and the experimental results should be viewed in this light. Our results emphasize the need to authenticate cell lines in oncologic research.
    The Journal of urology 03/2013; · 4.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: A Phase l trial of intravesical recombinant adenovirus-mediated interferon-α2b gene therapy (rAd-IFNα) formulated with the excipient SCH Syn3 was conducted in patients with non-muscle invasive bladder cancer (NMIBC) who recurred after Bacillus Calmette-Guerin (BCG). The primary objective was to determine the safety of rAd-IFNα/Syn3; secondary endpoints were to demonstrate effective rAd-IFNα gene expression and preliminary evidence of clinical activity at three months. PATIENTS AND METHODS: Seventeen patients with recurrent NMIBC after BCG were enrolled. A single treatment of rAd-IFNα (3x10(9) to 3x10(11) particles/mL) formulated with the excipient Syn3 was administered. Patient safety was evaluated for ≥12 weeks. Efficacy of gene transfer was determined by urine IFNα protein concentrations. Preliminary drug efficacy was determined at 3 months. RESULTS: Intravesical rAd-IFNα/Syn3 was well tolerated as no dose limiting toxicity (DLT) was encountered. Urgency was the most common adverse event and all were grade 1 or 2. rAd-IFNα DNA was not detected in the blood, however, transient low serum IFNα and Syn3 levels were measured. High and prolonged dose-related urine IFNα levels were achieved with the initial treatment. Of the 14 patients treated at doses ≥ 10(10) particles/mL with detectable urine IFNα, 6 (43%) experienced a complete response at 3 months and 2 remained disease free at 29.0 and 39.2 months respectively. CONCLUSION: Intravesical rAd-IFNα/Syn3 was well tolerated with no DLT encountered. Dose dependent urinary IFNα concentrations confirmed efficient gene transfer and expression. Intravesical rAd-IFNα/Syn3 demonstrated clinical activity in NMIBC recurring after BCG.
    The Journal of urology 03/2013; · 4.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic mechanism that can be measured by soluble forms of cytokeratin 18 (CK18) using M30 and M65 ELISAs, assays for caspase-cleaved (apoptotic) and uncleaved (necrotic) cell death, respectively. Therefore, we determined whether M30 and M65 levels in the urine after treatment could document all three mechanisms of cancer cell kill and also predict having a CR. High levels of both M30 and M65 were found in all patients within 24 h after treatment with all three types of cancer cell death occurring. Moreover, the return of both M30 and M65 levels in the urine to normal levels within 5 days or more after treatment was strongly associated with obtaining a CR (P=0.003). This is the first time that such assays have been used to study response to therapy in the urine of patients with bladder cancer and in the future may prove valuable in predicting clinical outcome.Cancer Gene Therapy advance online publication, 7 February 2014; doi:10.1038/cgt.2014.1.
    Cancer gene therapy 02/2014; · 3.13 Impact Factor

Full-text (2 Sources)

View
3 Downloads
Available from
May 23, 2014